Sequana Medical NV
XBRU:SEQUA

Watchlist Manager
Sequana Medical NV Logo
Sequana Medical NV
XBRU:SEQUA
Watchlist
Price: 0.85 EUR -1.16% Market Closed
Market Cap: 34.4m EUR
Have any thoughts about
Sequana Medical NV?
Write Note

Net Margin
Sequana Medical NV

-6 269.8%
Current
-4 735%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-6 269.8%
=
Net Income
-27.2m
/
Revenue
433.5k

Net Margin Across Competitors

Country BE
Market Cap 34.4m EUR
Net Margin
-6 270%
Country US
Market Cap 204.9B USD
Net Margin
14%
Country US
Market Cap 195.2B USD
Net Margin
29%
Country US
Market Cap 146.7B USD
Net Margin
16%
Country US
Market Cap 132.6B USD
Net Margin
11%
Country IE
Market Cap 110.6B USD
Net Margin
12%
Country US
Market Cap 64.7B USD
Net Margin
9%
Country DE
Market Cap 55.6B EUR
Net Margin
8%
Country CN
Market Cap 319.2B CNY
Net Margin
34%
Country US
Market Cap 41.6B USD
Net Margin
74%
Country US
Market Cap 37.7B USD
Net Margin
9%
No Stocks Found

Sequana Medical NV
Glance View

Market Cap
34.4m EUR
Industry
Health Care

Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

SEQUA Intrinsic Value
1.69 EUR
Undervaluation 50%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-6 269.8%
=
Net Income
-27.2m
/
Revenue
433.5k
What is the Net Margin of Sequana Medical NV?

Based on Sequana Medical NV's most recent financial statements, the company has Net Margin of -6 269.8%.